NCT00477282 2020-03-12
Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer
BioNumerik Pharmaceuticals, Inc.
Phase 3 Completed
Clinical Trials
6 trialsNCT00061308 2017-06-09
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01840943 2015-12-23
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Terminated
NCT00250094 2011-09-07
Clinical Benefit of Topoisomerase Downregulation
New Mexico Cancer Research Alliance
Phase 1 Completed
NCT00429559 2011-07-22
Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma
Hellenic Oncology Research Group
Phase 1/2 Completed
NCT00320983 2010-01-07
Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer
University of New Mexico
Phase 1 Completed